Integrated Synthetic, Biophysical, and Computational Investigations of Covalent Inhibitors of Prolyl Oligopeptidase and Fibroblast Activation Protein α

Journal of Medicinal Chemistry
2019.0

Abstract

Over the past decade, there has been increasing interest in covalent inhibition as a drug design strategy. Our own interest in the development of prolyl oligopeptidase (POP) and fibroblast activation protein α (FAP) covalent inhibitors has led us to question whether these two serine proteases were equal in terms of their reactivity toward electrophilic warheads. To streamline such investigations, we exploited both computational and experimental methods to investigate the influence of different reactive groups on both potency and binding kinetics using both our own series of POP inhibitors and others' discovered hits. A direct correlation between inhibitor reactivity and residence time was demonstrated through quantum mechanics methods and further supported by experimental studies. This computational method was also successfully applied to FAP, as an overview of known FAP inhibitors confirmed our computational predictions that more reactive warheads (e.g., boronic acids) must be employed to inhibit FAP than for POP.

Knowledge Graph

Similar Paper

Integrated Synthetic, Biophysical, and Computational Investigations of Covalent Inhibitors of Prolyl Oligopeptidase and Fibroblast Activation Protein α
Journal of Medicinal Chemistry 2019.0
Modulating the selectivity of inhibitors for prolyl oligopeptidase inhibitors and fibroblast activation protein-α for different indications
European Journal of Medicinal Chemistry 2022.0
Inhibition of prolyl oligopeptidase with a synthetic unnatural dipeptide
Bioorganic & Medicinal Chemistry 2010.0
Characterising covalent warhead reactivity
Bioorganic & Medicinal Chemistry 2019.0
A road map for prioritizing warheads for cysteine targeting covalent inhibitors
European Journal of Medicinal Chemistry 2018.0
Dicarboxylic Acid Azacycle <scp>l</scp>-Prolyl-pyrrolidine Amides as Prolyl Oligopeptidase Inhibitors and Three-Dimensional Quantitative Structure−Activity Relationship of the Enzyme−Inhibitor Interactions
Journal of Medicinal Chemistry 2005.0
Inhibitors of Prolyl Oligopeptidases for the Therapy of Human Diseases: Defining Diseases and Inhibitors
Journal of Medicinal Chemistry 2010.0
Covalent inhibitors design and discovery
European Journal of Medicinal Chemistry 2017.0
An electrophilic warhead library for mapping the reactivity and accessibility of tractable cysteines in protein kinases
European Journal of Medicinal Chemistry 2020.0
3-Oxo-hexahydro-1H-isoindole-4-carboxylic Acid as a Drug Chiral Bicyclic Scaffold: Structure-Based Design and Preparation of Conformationally Constrained Covalent and Noncovalent Prolyl Oligopeptidase Inhibitors
Journal of Medicinal Chemistry 2016.0